These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30397066)

  • 1. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
    Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
    Alghamdi WA; Antwi S; Enimil A; Yang H; Dompreh A; Wiesner L; Langaee T; Peloquin CA; Kwara A
    J Antimicrob Chemother; 2019 Sep; 74(9):2698-2706. PubMed ID: 31243456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
    Enimil A; Antwi S; Yang H; Dompreh A; Alghamdi WA; Gillani FS; Orstin A; Bosomtwe D; Opoku T; Norman J; Wiesner L; Langaee T; Peloquin CA; Court MH; Greenblatt DJ; Kwara A
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    Naidoo A; Chirehwa M; McIlleron H; Naidoo K; Essack S; Yende-Zuma N; Kimba-Phongi E; Adamson J; Govender K; Padayatchi N; Denti P
    J Antimicrob Chemother; 2017 May; 72(5):1441-1449. PubMed ID: 28175315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
    Bertrand J; Verstuyft C; Chou M; Borand L; Chea P; Nay KH; Blanc FX; Mentré F; Taburet AM;
    J Infect Dis; 2014 Feb; 209(3):399-408. PubMed ID: 23990572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.
    Kwara A; Enimil A; Gillani FS; Yang H; Sarfo AM; Dompreh A; Ortsin A; Osei-Tutu L; Kwarteng Owusu S; Wiesner L; Norman J; Kurpewski J; Peloquin CA; Ansong D; Antwi S
    J Pediatric Infect Dis Soc; 2016 Dec; 5(4):356-365. PubMed ID: 26407268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
    McIlleron HM; Schomaker M; Ren Y; Sinxadi P; Nuttall JJ; Gous H; Moultrie H; Eley B; Merry C; Smith P; Haas DW; Maartens G
    AIDS; 2013 Jul; 27(12):1933-40. PubMed ID: 24180002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
    Luetkemeyer AF; Rosenkranz SL; Lu D; Marzan F; Ive P; Hogg E; Swindells S; Benson CA; Grinsztejn B; Sanne IM; Havlir DV; Aweeka F;
    Clin Infect Dis; 2013 Aug; 57(4):586-93. PubMed ID: 23592830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
    Sinha S; Raghunandan P; Chandrashekhar R; Sharma SK; Kumar S; Dhooria S; Ekka M; Velpandian T; Ranjan S; Ahmad H; Samantaray JC; Venkatesh S; Rewari BB; Khan NH; Pandey RM
    BMC Infect Dis; 2013 Oct; 13():482. PubMed ID: 24134449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
    Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
    Chirehwa MT; McIlleron H; Wiesner L; Affolabi D; Bah-Sow O; Merle C; Denti P;
    J Antimicrob Chemother; 2019 Jan; 74(1):139-148. PubMed ID: 30239829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
    Dooley KE; Luetkemeyer AF; Park JG; Allen R; Cramer Y; Murray S; Sutherland D; Aweeka F; Koletar SL; Marzan F; Bao J; Savic R; Haas DW;
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5245-52. PubMed ID: 24957823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).
    Borand L; Madec Y; Laureillard D; Chou M; Marcy O; Pheng P; Prak N; Kim C; Lak KK; Hak C; Dim B; Nerrienet E; Fontanet A; Sok T; Goldfeld AE; Blanc FX; Taburet AM
    PLoS One; 2014; 9(3):e90350. PubMed ID: 24608960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.